Correlation Between Hansa Biopharma and Nanoform Finland

Can any of the company-specific risk be diversified away by investing in both Hansa Biopharma and Nanoform Finland at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hansa Biopharma and Nanoform Finland into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Hansa Biopharma AB and Nanoform Finland Plc, you can compare the effects of market volatilities on Hansa Biopharma and Nanoform Finland and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hansa Biopharma with a short position of Nanoform Finland. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hansa Biopharma and Nanoform Finland.

Diversification Opportunities for Hansa Biopharma and Nanoform Finland

0.02

Correlation Coefficient

Hansa Biopharma  Nanoform Finland

Significant diversification

The 3 months correlation between Hansa and Nanoform is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Hansa Biopharma AB and Nanoform Finland Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nanoform Finland Plc and Hansa Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hansa Biopharma AB are associated (or correlated) with Nanoform Finland. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nanoform Finland Plc has no effect on the direction of Hansa Biopharma i.e., Hansa Biopharma and Nanoform Finland go up and down completely randomly.

Pair Corralation between Hansa Biopharma and Nanoform Finland

Assuming the 90 days trading horizon Hansa Biopharma AB is expected to generate 0.73 times more return on investment than Nanoform Finland. However, Hansa Biopharma AB is 1.37 times less risky than Nanoform Finland. It trades about 0.08 of its potential returns per unit of risk. Nanoform Finland Plc is currently generating about 0.03 per unit of risk. If you would invest  2,230  in Hansa Biopharma AB on April 23, 2025 and sell it today you would earn a total of  392.00  from holding Hansa Biopharma AB or generate 17.58% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.36%
Values	Daily Returns

Hansa Biopharma AB  vs.  Nanoform Finland Plc

Hansa Biopharma AB

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Hansa Biopharma AB are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Hansa Biopharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Nanoform Finland Plc

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Nanoform Finland Plc are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Nanoform Finland may actually be approaching a critical reversion point that can send shares even higher in August 2025.

Pair Trading with Hansa Biopharma and Nanoform Finland

The main advantage of trading using opposite Hansa Biopharma and Nanoform Finland positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hansa Biopharma position performs unexpectedly, Nanoform Finland can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nanoform Finland will offset losses from the drop in Nanoform Finland's long position.

The idea behind Hansa Biopharma AB and Nanoform Finland Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.